We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breakthrough Blood Test Developed For Schizophrenia Predicts Most Effective Treatments

By LabMedica International staff writers
Posted on 12 Feb 2024

Millions of people worldwide are affected by psychotic disorders, with psychosis typically emerging in young adulthood — a crucial phase of life. Stress and substance use, including marijuana, can trigger psychosis in individuals with a genetic predisposition. Without intervention, psychosis can lead to escalating biological, social, and psychological harm. Schizophrenia, a psychiatric condition characterized by hallucinations and delusions, is challenging to diagnose, particularly in its early stages. It is crucial to match individuals with the most effective treatment from the outset. Now, a new test developed for schizophrenia is capable of identifying biomarkers in a person's blood. This test objectively evaluates their current severity and future risk for the disorder and aligns them with treatments that are most suitable for their unique biological makeup.

In a study, a team of researchers led by Indiana University School of Medicine (Indianapolis, IN, USA) observed psychiatric patients for over a decade. The team identified biomarkers indicative of high hallucination and delusion states, as well as those predictive of future psychiatric hospitalizations related to these symptoms. They also determined which biomarkers are affected by existing drugs, facilitating the alignment of patients with appropriate treatments. This research builds upon two decades of work by the team on blood biomarkers for various psychiatric conditions, including mood disorders, anxiety, post-traumatic stress disorder, suicidality risk, pain, and memory disorders. Notably, the identified biomarkers were found to be more predictive than standard evaluation scales for hallucinations and delusions. This implies that the biomarker test can help minimize subjectivity and uncertainty in psychiatric assessments. The test is expected to be commercially available later this year.


Image: A new blood test predicts psychosis risk and the most effective treatments (Photo courtesy of 123RF)
Image: A new blood test predicts psychosis risk and the most effective treatments (Photo courtesy of 123RF)

Related Links:
Indiana University School of Medicine


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroxine ELISA
T4 ELISA
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest Molecular Diagnostics News

AI Urine Test Predicts COPD Flares Before Symptoms Appear

New Liquid Biopsy Panel Targets Pediatric Cancers

Finger Prick Blood Test to Enable Early Alzheimer’s Detection